---
title: "MediciNova Concludes Phase 2 For MN-001 In Treating Diabetic Non-Alcoholic Fatty Liver Disease"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287743284.md"
description: "MediciNova Inc. has completed the last patient visit in its Phase 2 trial of MN-001 for treating hypertriglyceridemia and non-alcoholic fatty liver disease in type-2 diabetes patients. The trial assessed MN-001's efficacy over 24 weeks, with results expected in Q3 2026. The company is also advancing MN-001 in trials for idiopathic pulmonary fibrosis and non-alcoholic fatty liver disease. MNOV shares closed at $1.37, down 2.14%."
datetime: "2026-05-27T09:00:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287743284.md)
  - [en](https://longbridge.com/en/news/287743284.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287743284.md)
---

# MediciNova Concludes Phase 2 For MN-001 In Treating Diabetic Non-Alcoholic Fatty Liver Disease

(RTTNews) - MediciNova Inc. (MNOV), a clinical-stage biopharmaceutical company, on Tuesday announced the completion of the last patient, last visit in its Phase 2 trial of MN-001 for hypertriglyceridemia and non-alcoholic fatty liver disease associated with type-2 diabetes mellitus.

Type-2 diabetes mellitus (T2DM) is marked by insulin resistance and can cause an abnormal buildup of unwanted lipids in the body, which is known as dyslipidemia. Hypertriglyceridemia and hypercholesterolemia are commonly observed in T2DM patients due to increased hepatic lipid synthesis, leading to non-alcoholic fatty liver disease (NAFLD).

MN-001 (tipelukast) is a novel, orally bioavailable, small molecule compound that has shown anti-inflammatory and anti-fibrotic activity in preclinical models by inhibiting certain fibrosis pathways and down-regulating pro-inflammatory genes.

The Phase 2 MN-001-NATG-202 trial was a multicenter, randomized, double-blind, placebo-controlled study assessing MN-001 in T2DM patients over 24 weeks. The co-primary endpoints were a reduction in liver fat content and serum triglycerides from a baseline to levels at week 24. Topline results are expected in the third quarter of 2026.

The company is also advancing MN-001 in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF), and in another Phase 2 trial for NAFLD. Lead drug candidate MN-166 (ibudilast) is in Phase 3 studies for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM). It is also being evaluated in treating progressive multiple sclerosis (MS), Long COVID, and substance abuse.

MNOV closed Tuesday at $1.37, down 2.14%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [MNOV.US](https://longbridge.com/en/quote/MNOV.US.md)
- [4875.JP](https://longbridge.com/en/quote/4875.JP.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Analyst Reiterates Buy on MediciNova as Advancing Pipeline and Upcoming ALS Catalysts Support Unchanged $6 Price Target](https://longbridge.com/en/news/291454858.md)
- [NewcelX prices USD 1.4 million private placement at USD 4.03 per share](https://longbridge.com/en/news/294517143.md)
- [FibroBiologics Q2 2026 Earnings: CYWC628 Dosing Begins With $3.5 Million in Cash](https://longbridge.com/en/news/294918582.md)
- [Seven Fleet Capital Management LP Acquires New Shares in Alkermes plc $ALKS](https://longbridge.com/en/news/294604011.md)
- [BLUEDART: FY2025-26 revenue reached ₹61,409 mn, with strong margins and sustained market leadership](https://longbridge.com/en/news/294823162.md)